We have learned of an anticipated drug shortage that may affect some epilepsy patients in Canada.
The product shortage affects SABRIL (vigabatrin), in the 500 mg powder for oral solution only. Stock of 500 mg SABRIL tablets remains available.
The shortage is expected to begin in early August, and at this time it is unknown when the powder for oral formulation of SABRIL will be back in stock.
Patients affected by this shortage are encouraged to reach out and consult with their healthcare professional, who can make a decision about their treatment plan. Additional questions and medical information inquiries can also be directed to Lundbeck Canada Medical Information at 1-866-880-4636 or firstname.lastname@example.org.